SLUCare picks Medial EarlySign’s AI tool to flag patients at risk for lower GI disorders

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email
SLUCare chooses Medial EarlySign AI

SLUCare picks Medial EarlySign’s AI tool to flag patients at risk for lower GI disorders

Medial EarlySign’s LGI Flag solution is a machine learning-based tool that uses medical data to pinpoint those at risk for lower GI disorders associated with chronic occult bleeding.

 

SLUCare Physician Group, the academic medical practice of Saint Louis University, has announced a partnership with Medial EarlySign, a startup leveraging AI technology to predict which individuals are at risk for specific health conditions.

 

Through it, SLUCare will implement the company’s LGI Flag solution in its patient care offices this month. The machine learning-based tool uses medical data to pinpoint those at risk for lower GI disorders associated with chronic occult bleeding. These include polyps, irritable bowel disease, diverticulitis, ulcers, precancerous adenomas and colorectal cancer.

 

SLUCare chooses Medial EarlySign AI

 

LGI Flag uses data collected over the course of routine care, as well as machine learning techniques. Providers can then focus on patients who would benefit from additional evaluation and possible intervention.

 

“By seeking provider input, we better understand the challenges they face and can help with the early detection of severe illness,” Medial EarlySign CMO Jeremy Orr said in a statement. “This is part of our approach — to understand the practical aspects of putting these predictors into clinical practice. Great models fail if they are not well implemented.”

 

Founded in 2009 and headquartered in Israel, Medial EarlySign also uses its model to provide insights on other chronic and acute conditions like diabetes and cancers. “Prior to founding the company, we actually spent a few years … investigating what could be done with existing health records and what we can harvest from these kinds of data using different approaches of machine learning,” company co-founder and CEO Ori Geva said in a phone interview in 2017.

 

The startup and SLUCare were introduced through BioSTL’s GlobalSTL initiative. BioSTL is a nonprofit organization fostering bioscience innovation in St. Louis. The GlobalSTL initiative seeks to recruit international companies to establish a U.S. headquarters in St. Louis.

 

Read the full article here.

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Are you looking to solve high-burden disease challenges?